ArticleFrontiers in aging neuroscience2025
Bioinformatics and experimental validation identify biomarkers for diagnosing Alzheimer's disease.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the Potential Neurotoxic Links Between 6PPD/6PPD-Q and Parkinson's Disease Through Network Toxicology and Multi-Dimensional Bioinformatics Analysis.Neurotoxicity research · 2026Article
- Neuronal subtype-specific ribosomal protein mRNA expression.RNA (New York, N.Y.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Alzheimer's disease (AD) is a complex condition involving multiple mechanisms, primarily characterized by the progressive decline in cognition and memory. At present, there is no simple and reliable diagnostic method available for clinical application. Therefore, this study aims to identify potential biomarkers for AD using bioinformatics, providing new insights into its diagnosis. Methods: This study utilized the transcriptome dataset GSE63060 from the Gene Expression Omnibus (GEO) and applied bioinformatics approaches to identify candidate genes. Differentially expressed genes (DEGs), weighted gene co-expression network analysis (WGCNA), protein-protein interaction (PPI) networks, and machine learning techniques (LASSO, SVM-RFE, Boruta, and XGBoost) were employed on the GSE63060 dataset. Subsequently, the expression levels of the candidate genes were evaluated, and a receiver operating characteristic (ROC) curve was constructed to identify hub genes and establish a corresponding network. Finally, we focused on the common upstream transcription factor c-Myc among the hub genes and conducted clinical experiments to validate its potential. Serum samples were collected from 41 AD patients treated at the Second Affiliated Hospital of Harbin Medical University between October 2023 and November 2024, along with 41 control subjects. The c-Myc protein concentration was measured using ELISA, and a ROC curve was constructed to assess its diagnostic potential. Results: This study identified four hub genes associated with AD: RPL36AL, NDUFA1, NDUFS5, and RPS25. Additionally, the concentration of the c-Myc protein was significantly different between the AD and control groups ( Conclusion: Our study demonstrates that RPL36AL, NDUFA1, NDUFS5, and RPS25 have potential as biomarkers for the diagnosis of AD. Additionally, the experiment suggests that c-Myc could serve as a promising blood biomarker for the diagnosis of AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.